2 active not recruiting, 2 recruiting, 1 not yet recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Recruiting 2, Not yet recruiting 1 |
Follow Lung Neuroendocrine Neoplasm: new trials by email Literature Review of Lung Neuroendocrine Neoplasm trials Research Report on Lung Neuroendocrine Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant - Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 60 | 2026-12-15 | 2026-10-20 |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Everolimus - Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2023-02-03 | 2026-10-19 |
| A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) Cabozantinib and Temozolomide - Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor | Phase 2 | Recruiting | National Cancer Institute, Naples | 35 | 2021-06-15 | 2024-06-18 |
| Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors CVM-1118 - Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor | Phase 2 | Active not recruiting | TaiRx, Inc. | 34 | 2018-12-15 | 2025-12-23 |
| Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer Nivolumab, Stereotactic Body Radiation Therapy - Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 140 | 2017-06-26 | 2026-06-22 |
Adenoma, Islet Cell (2) · Carcinoma, Neuroendocrine (2) · Gastro-enteropancreatic neuroendocrine tumor (2) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Neoplasms (1) · Neuroendocrine Tumors (1)
Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Adenoma (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Neoplasms (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Pancreatic Diseases (2)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Temozolomide (2) · Colony-Stimulating Factors (1) · Everolimus (1) · Fluorodeoxyglucose F18 (1) · Nivolumab (1) · Photons (1) · Radiosurgery (1) · X-Rays (1) · cabozantinib (1) · incomplete Freund's adjuvant (1) · lutetium Lu 177 dotatate (1) · montanide ISA 51 (1) · sargramostim (1)
M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · National Cancer Institute, Naples (1) · Roswell Park Cancer Institute (1) · TaiRx, Inc. (1)
United States (3) · Italy (1) · Taiwan (1)
Jasmeet Kaur, MD (1) · Joe Y Chang (1) · Thomas A Hope (1) · Wu-Chou Su (1)
PMID 37478883, PMID 41963331, PMID 42393461
U10CA180821 (1)